Abstract
Fosdenopterin (NulibryTM) is a synthetic cyclic pyranopterin monophosphate that is being developed by Origin Biosciences (a subsidiary of BridgeBio Pharma) for the treatment of molybdenum cofactor deficiency (MoCD) type A. Fosdenopterin was recently approved by the US FDA for use in reducing the risk of mortality in paediatric and adult patients with MoCD type A. This article summarizes the milestones in the development of fosdenopterin leading to this first approval.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schwarz G. Molybdenum cofactor and human disease. Curr Opin Chem Biol. 2016;31:179–87.
Atwal PS, Scaglia F. Molybdenum cofactor deficiency. Mol Genet Metab. 2016;117(1):1–4.
Origin Biosciences. NULIBRY (fosdenopterin) for injection, for intravenous use: US prescribing information. 2021. https://www.nulibry.com/pdfs/nulibry-prescribing-information.pdf. Accessed 6 Apr 2021.
US Food & Drug Administration. FDA approves first treatment for molybdenum cofactor deficiency type A [media release]. Feb 26 2021. https://www.fda.gov.
Alexion Pharmaceuticals. Alexion acquires investigational therapy for infants suffering from catastrophic, ultra-rare genetic neurologic disorder [media release]. 11 Feb 2011. http://www.alexionpharma.com.
BridgeBio Pharma. BridgeBio Pharma enters into agreement to acquire late stage therapy for ultra-rare disorder from Alexion; launches Origin Biosciences to develop and commercialize therapy [media release]. 11 Jun 2018. http://www.bridgebio.com.
BridgeBio Pharma. BridgeBio Pharma's Origin Biosciences enters partnership with Medison to commercialize BBP-870 in Israel for MoCD type A [media release]. 18 Dec 2019. http://www.bridgebio.com.
United States Securities and Exchange Commission. Form S-1 Registration Statement. 2019. https://www.sec.gov. Accessed 6 Apr 2021.
Funding
The preparation of this review was not supported by any external funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Authorship and conflict of Interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Rights and permissions
About this article
Cite this article
Kang, C. Fosdenopterin: First Approval. Drugs 81, 953–956 (2021). https://doi.org/10.1007/s40265-021-01520-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-021-01520-2